# INDEX TO VOLUME 169

## Author Index


Aaby, P., 581
Abbo, H., 956
Abou-Zeid, C., 162
Abrams, D., 384
Aceti, A., 1176
Achim, C. L., 623
Ackermann, R., 313
Acyclovir Study Group, 1338
Adams, K., 1166
Adams, R. B., 170
Ades, E. W., 430
Adreana, A., 760
Adubofour, K. O., 639
Agarossi, A., 1112
Agbaria, R., 9
AIDS Clinical Trials Group Virology Laboratories, 713
Aintablian, N., 91
Ala-Kaila, Kyösti, 1023
Alam, J., 37
Alam, K., 230, 709
Albert, J., 611
Albert, M. J., 230, 709
Alexander, J. P., Jr., 905, 1133
Aliaga, G. R., 452
Ali-Salaam, P., 568
Allegra, C. J., 456, 1414
Allison, C., 1155
Allison, L., 1374
Allred, R., 214
Almondo, F., 1401
Alonso, P. L., 1390
Altamirano, M., 1162
Alter, M. J., 990
Ambroise-Thomas, P., 1181
Ameglio, F., 886
Amir, J., 912
Amos, G., 350
Anderson, E. L., 1121
Anderson, L. J., 905, 1133
Ando, D., 369
Andrawis, V., 456
Andremont, A., 821
Angarano, G., 611
Ansaruzzaman, M., 230
Apicella, M. A., 1146
Araujo, E., 588
Araujo, F. G., 375
Arbeit, R. D., 526
Arduino, J. M., 713
Arduino, M., 1166
Armstrong, G. D., 1291
Arora, D. J. S., 1129
Aruajo, E., 686
Arvilommi, H., 1023
Asato, T., 940
Ash, R. C., 775
Ashley, R., 754, 962
Atkins, J. T., 1334
Aukerman, S. L., 369
Aukrust, P., 420, 889
Austrian, R., 212
Autenrieth, I. B., 562
Awadzi, K., 1071
Aydinli, K., 704
Babbitt, J., 775
Babilis, G. C., 853
Bacher, J., 356, 553
Bacq, Y., 1411
Baden, L., 905
Badger, G., 1
Badur, S., 704
Bailleux, F., 399
Baird, R. W., 319
Baker, C., 438
Balasubramanian, K. A., 538
Baldini, N., 1175
Balfour, H. H., Jr., 713
Bandea, C. I., 281
Bangham, C. R. M., 941
Banks, S. M., 553
Bantel-Schaal, U., 223
Barbanti-Brodano, G., 1175
Barber, K. A., 875
Barbhaiya, R. H., 1250
Barbour, A. G., 445
Barea, P. L., 1401
Barenkamp, S. J., 425
Barin, F., 1411
Barnett, E. M., 782
Barozzi, P., 943
Barratt, R. A., 647
Barrett, A. D. T., 512
Barrett, T. J., 1381
Bartelink, A. K. M., 157
Barthold, S. W., 568
Bartz, C., 260
Baseler, M., 981
Bayley, A. C., 706
Beaman, M. H., 375
Bean, N. H., 1381
Beasley, D., 1014
Becker, S., 1166
Beckett, L. A., 713
Beingolea, L., 1381
Belshe, R. B., 996, 1121, 1125
Beltangady, M., 1250
Beltrán, P., 1412
Benedetto, A., 1176
Benfield, T. L., 1170
Benveniste, R. E., 260
Beratis, N. G., 853
Berche, P., 449
Berg, C. M., 1384
Berg, D. E., 1384
Berger, D., 41
Bergeron-Lynn, G., 642
Berhe, N., 707
Bermudez, L. E., 575
Berner, R., 562
Bernstein, D. I., 900
Besch, C. L., 384
Best, L. M., 434
Bettens, F., 1416
Betts, R., 402
Bezanson, G. S., 434
Bhat, G. H., 897
Bhattarcharya, M. K., 1029
Bhattacharya, S. K., 1029
Bicchieri, R., 1297
Bickel, U., 55
Bienzle, U., 467
Bijlmer, H. A., 673
Bikin, D. S., 689
Billstein, S. A., 937
Biron, F., 696
Bischofberger, N., 260
Bistoni, F., 1325
Black, W. A., 1162
Blackwood, V., 847
Blake, P., 547
Bland, L., 1166
Blaser, J., 1397
Blaser, M. J., 1177
Blatt, S. P., 1356
Block, C., 912
Bockenstedt, L. K., 568
Bodey, G. P., 350
Bodhidatta, L., 916
Bodkin, D., 1368
Boeckh, M., 769
Boelaert, J. R., 231
Boisot, S., 1042
Boldin, M., 919
Bonis, J., 225
Boone, G. S., 1338
Bouchara, J. P., 683
Boucher, C. A. B., 1346, 1351
Boudreau, E., 595
Bourne, N., 1084
Bowers, F. S., 253
Bowman, B. H., 1050
Boyle, M. D. P., 143
Bozzette, S. A., 968
Bradley, J. E., 588
Brandts, C., 467
Bratt, G., 1096
Bravo, F. J., 947
Brawley, O. W., 9
Bremner, J. A. G., 938
Brenner, F. H., 547
Brinchmann, J. E., 730
Briss, P. A., 77
Britt, W., 83
Broder, S., 9
Brodie, S. J., 653
Bronze, M. S., 319
Brousse, N., 449
Brown, C. C., 975
Brown, L. S., 384
Brundage, J., 1
Bubp, J., 416
Buciak, J., 55
Buck, G., 1166
Buescher, S., 1419
Buffone, G. J., 1334
Bukawa, H., 227
Bulkow, L. R., 793
Bunin, N., 775
Bunnag, D., 595
Burke, D. S., 48
Busch, M., 1219
Buseyne, F., 274
Butzin, C., 1356
Cadavid, D., 445
Cairns, J., 706
Calabrese, L. H., 1360
Calsyn, D., 962
Cameron, D. W., 1103
Camitta, B., 775
Campagnari, A. A., 1146
Campbell, P. W., 241
Candal, F. J., 430
Cannella, D., 696
Cannon, C. G., 703
Cannon, J. G., 532
Cannon, R. O., 990
Cantelli, C., 1401
Capeding, M. R. Z., 479
Capobianchi, M. R., 886
Caprioli, A., 208
Cararach, V., 1390
Carbon, C., 218, 821, 1318
Carithers, R., Jr., 1219
Carlo, D. J., 1256
Carlone, G. M., 847
Carpenter, A., 343
Carrigan, D. R., 775
Carrillo, C., 754
Caruz, A., 267
Casper, J. T., 775
Cassell, M., 782
Castilletti, C., 886
Cate, T. R., 477
Caugant, D. A., 673
Cave, M. D., 189
Cenci, E., 1325
Cenini, P., 707
Chai, T., 871
Chamberlin, C. J., 91
Chambers, S. T., 839
Chandler, B., 642
Chang, C.-m., 633
Chang, M.-H., 638
Chang, S.-F., 222, 936
Chang, T.-H., 633

Chantra, A., 932
Chao, C. C., 1092
Charniga, L., 532
Chau, K. H., 801
Chauveau, P., 399
Chen, D.-S., 229, 638
Chen, M., 568
Chen, P.-J., 638
Chen, S.-E., 936
Cherry, J. D., 766
Chevret, S., 882
Child, C., 384
Childs, J. E., 1271
Chin, D. P., 289
Chintu, C., 614
Chongsuphajaisiddhi, T., 595
Chonmaitree, T., 1265
Chou, S., 769
Chouchane, L., 253
Chu, E., 456
Chumdermpadetsuk, S., 228
Cieslak, T. J., 324
Clancy, K. A., 1108
Clark, A. M., 1284
Clark, C. G., 483
Clark, I. A., 1071
Clemens, R., 932
Clemons, K. V., 859
Cohen, B. J., 938
Cohen, J., 343
Cohen, M. S., 532
Cohn, D., 193
Coleman, N., 1155
Coligan, J. E., 496
Collier, A. C., 37, 1342
Collman, R., 746
Cone, R. A., 647
Cone, R. W., 1342
Conlon, C. P., 411
Connelly, B. L., 1084
Conrad, P. A., 923, 1050
Conti, M., 1112
Conti, S., 1401
Cooksley, W. G. E., 871
Coombs, R. W., 37, 713, 722
Cooper, D. A., 1346
Cooper, E. S., 692
Corey, L., 37, 41, 956, 1219, 1342
Corradin, S. B., 105
Cot, S., 1417
Couch, R. B., 477
Coukos, G., 746
Couroucé, A.-M., 399
Courtney, H. S., 319
Coutifaris, C., 746
Coutinho, R. A., 1236, 1244
Cozon, G., 696
Cravioto, A., 1412
Cross, A. S., 112
Crowe, J. S., 875
Crumpacker, C. S., 1338
Cryz, S. J., Jr., 228, 1159
Cutlip, R. C., 814
Dachman, W. D., 689
Daenke, S., 941
Dagan, R., 912
Daigle, A., 1256
Dale, J. B., 319
D'Alessandro, U., 702
D'Amaro, J., 1244
Dandekar, S., 1116
Daniel, P. F., 538
Dankert, J., 673
Dankner, W. M., 491
Danner, R. L., 553
da Silva, A. P. J., 581
Dautrey, S., 218
Davachi, F., 975
Daves, B., 1166
Davey, R. T., 981
Davidson, M., 793
Davies, S. L., 875
Davis, J. C., 1174
Davis, J. R., 927
Davis, R. W., 859
Dawson, G. J., 801
Days, A., 588
Deb, B. C., 1029
DeBey, B. M., 814
de Boer, J. B., 1351
Debs, R. J., 1088
De Clercq, E., 642
De Gruttola, V., 713
de Jong, M. D., 1346
DeJoy, S. Q., 150
de la Concha-Bermejillo, A., 653
Delage, G., 473
dela Rosa, C., 1219
Delgado, G., 1412
Delia, S., 1179
Dellagi, K., 1183
Dell'Isola, B., 449
de Locht, M., 231
Demacker, P., 1306
Demacker, P. N. M., 157
DeMartini, J. C., 653
De Mattei, M., 1175
Demmler, G. J., 1334
Denis, F., 225
de Pauw, B. E., 1062
DeRousse, C., 996
DeSantis, R. A., 1133
Detels, R., 766
De Veranez, D., 193
Devillier, P., 399
De Vries, R. R. P., 162
de Waal, L. P., 1244
de Wit, J., 1236
de Wit, T. F. R., 162
Deyton, L., 384
Dharmana, E., 1306
Diagne, A., 55
Diamond, L. S., 483
Dianzani, F., 886
Diese, M., 296
Dieterich, D. T., 178
Diglisic, G., 204
Dinarello, C. A., 480, 1007
Diven, W. F., 919
Djokomoeljanto, R., 1306
Dobloug, J. H., 730
Dolin, R., 1250
Dolmans, W. M. V., 1306
Donnenberg, M. S., 831
Dowd, P., 1351
Dragavon, J., 41
Dressler, F., 313
Drijfhout, J. W., 162
Drobniewski, F., 1180
Drobyski, W. R., 775
Dubois, F., 475, 1411
Dumas, M., 225
Dumitrescu, O., 281
Dumyati, G., 402
Dunkle, L. M., 1250
DuPont, H. L., 614, 897
Dupont, W. D., 68
Eberhard, M. L., 1050
Echeverria, P., 916
Economidis, J. J., 853
Edefonti, A., 208
Edwards, A., 411
Edwards, K. M., 68
Egeland, T., 730
Eggert, E., 37
Eibl, M. M., 1407
Eisenach, K. D., 189
Elbeik, T., 879
Elin, R. J., 553
Eling, W. M. C., 1417, 1418
El-Shewy, K., 460
Elson, L. H., 588, 686
Elting, L., 350
Emödy, L., 1155
Ennis, F. A., 200
Enscore, R. E., 1271
Enssle, K.-H., 1325
Erb, S., 402
Escamilla, J., 754
Esko, E., 337
Eslava, C., 1412
Espevik, T., 420
Espinosa, L. R., 1360
Essex, M., 296, 628
Estes, M. K., 504, 1364
Etkind, P., 1297
Evans, G., 782
Evans, M. E., 472
Evans, T., 343
Excler, J. L., 399
Ezzell, R. M., 95
Faden, H., 1312
Fainstein, V., 350
Fairfax, M. R., 1342
Fais, S., 886
Falkow, S., 337
Fang, G., 170
Farina, C., 208
Farinotti, R., 218, 1318
Fauci, A. S., 975
Fehrs, L. J., 77
Felgenhauer, K., 1138
Ferre, F., 1256
Fidler, J. M., 369
Fife, K. H., 1338
Fikrig, E., 568, 668
Filley, E., 162
Finegan, C. K., 18
Fiore, J., 611
Fischer, C. L., 48
Fischer, G. W., 324
Fischl, M. A., 713
Fiscus, S., 722
Fisher, L. D., 962
Fisicaro, P., 1401
FitzGerald, M., 1162
Fitzgerald, M. A., 793
Flaegstad, T., 485
Flavell, R. A., 568
Fleisher, B., 1142
Fløe, R., 485
Flomenberg, P., 775
Flores-Aguilar, M., 642
Flower, A. J. E., 62
Fluckiger, U., 1397
Follis, K. E., 260
Forman, S. J., 1088
Forstner, J. F., 1002
Forthal, D. N., 1377
Fortuin, M., 1374
Foulke, D. T., 441
Foung, S. K. H., 620
Fournel, M., 214
Fouts, T. R., 927
Fowler, A. K., 48
Fowler, K. B., 937
Fox, I., 37
Francesconi, A., 356
Francioli, P., 1397
Francis, H., 1071
Francis, P., 356
François, M., 1411
Freeman, W. R., 642
Frey, J. K., 1271
Friedman, H., 1177
Fries, B. C., 769
Frissen, P. H. J., 1351
Frøland, S. S., 420, 889
Frommel, D., 707
Frothingham, R., 305
Frottier, J., 882
Frye, S., 1138
Fuchs, D., 224
Fujisawa, Y., 787
Fürer, E., 1159
Gage, K. L., 1271
Gallati, H., 157, 1306
Gallay, P., 105
Galli, M., 1112
Gallicano, K., 1103
Gam, A. A., 692
Gam, A. A., 1076
Gann, P. H., 1076
Garg, S., 1029
Garofalo, R., 1265
Gary, H. E., Jr., 1108
Gasem, M. H., 1306
Gaspari, A. A., 1146
Ge, Y., 95

Gekker, G., 1092
Gelfand, J. A., 480
Gemmill, R., 1
Gentile, M., 886
George, V. G., 430
Gerloni, M., 1401
Gewert, D. R., 875
Giam, C.-Z., 496
Gianviti, A., 208
Gibson, C. A., 512
Gillis, S., 1007
Ginsberg, M. M., 703
Giorgi, J. V., 766
Girardin, H., 683
Glass, A. G., 235
Glauser, M. P., 105, 1397
Gligic, A., 204
Glück, R., 228
Godfrey-Faussett, P., 1180
Godfried, M. H., 739
Goff, E., 1088
Goglio, A., 208
Goldbaum, G. M., 189
Golding, J., 1409
Goldmann, D. A., 526, 1042
Goldstein, F., 1318
Gollapudi, S., 760
Gonin, R., 1368
González, A. R., 1412
Gonzalez, C., 927
Gonzalez-Scarano, F., 746
Gordin, F. M., 893
Gormus, B., 296
Górny, A., 1360
Gotoff, R., 200
Gottschau, A., 581
Gottstein, B., 1416
Gotuzzo, E., 754
Goudeau, A., 475, 1411
Goudsmit, J., 1236
Goulet, O., 449
Goullet, P., 119
Graninger, W., 467, 710
Granowitz, E. V., 480
Grant, I., 384
Grant, R. F., 260
Grasela, T. H., 1250
Gratacós, E., 1390
Gravitt, P. E., 235
Green, K. Y., 1364
Greenberg, P. D., 41
Greene, K. D., 1035
Greenwood, A. M., 702
Greenwood, B. M., 702
Greer, C. E., 235
Gresham, L. S., 703
Gretch, D., 1219
Griffin, P. M., 1035
Gross, S. K., 538
Grout, M., 1042
Gruber, W. C., 241
Guderian, R. H., 588, 686
Gudipati, S., 996
Guelde, G., 553
Guerrant, R. L., 170, 1206
Gumerlock, P. H., 661
Gundacker, H. M., 28
Gupta, P., 722
Gupta, R., 197
Gupta, S., 760
Gutierrez, N., 1042
Gutierrez, R., 801
Gutmann, L., 1318
Gwaltney, J. M., Jr., 1007
Haaheim, L. L., 730
Haas, J., 1138
Habis, A., 1377
Hadley, W. K., 289
Haefelin, D. N., 223
Hafner, R., 384
Hailu, A., 707
Haining, W. N., 425
Hall, D., 1346
Haller, O., 807
Hamajima, K., 227
Hamilton, J. D., 893
Hampton, M. B., 839
Han, J., 1219
Harabuchi, Y., 1312
Harekeh, H., 847
Hart, J., 1219
Hartigan, P. M., 893
Hasty, D. L., 319
Haug, C., 889
Haverkamp, G., 1351
Hazama, M., 787
Hebel, J. R., 831
Heerze, L. D., 1291
Heesemann, J., 562
Hegazi, M. M., 460
Heger, B. H., 730
Hegerich, P. A., 48
Heimdahl, A., 1096
Heise, C., 1116
Hekman, A., 1244
Helfand, R. F., 1133
Hemming, V. G., 324, 1368
Hendley, J. O., 1007
Hennessey, K., 766
Henrichon, M., 1129
Heppner, D. G., 927
Hernando, F. L., 1401
Herrmann, J., 916
Herwaldt, B. L., 1050
Hetherington, S. V., 248
Heumann, D., 105
Heyworth, M. F., 395
Higashi, M., 940
Higham, S., 1297
Hildesheim, A., 235
Hill, E. L., 1338
Hinuma, S., 787
Hirschhorn, L. R., 127
Ho, H.-N., 222
Hoare, S., 1374
Hochkeppel, H. K., 807
Hoen, T. E., 647
Hoenig, E., 18
Hoepelman, A. I. M., 1351
Hoffman, A., 356
Hoffman, M. C., 41
Hoffman, S., 927
Hoffman, W. D., 553
Hofmann, B., 1170
Hoge, C. W., 916
Højlyng, N., 581
Hollinger, F. B., 713
Holm, S. E., 519
Holmes, K. K., 754, 962
Hom, D. L., 18
Hone, D., 927
Hong, J. J., 1312
Hook, E. W., III, 990
Hooton, T. M., 189
Hopewell, P. C., 289
Horisberger, M. A., 807
Horowitz, M. M., 775
Horsburgh, C. R., Jr., 289
Hoshino, H., 620
Hosseini, J. M., 553
Hovanessian, A., 807
Howard, C., 1374
Howard, E. J., 939
Howie, V. M., 1265
Hsu, H.-Y., 638
Hu, C.-P., 633
Hu, S., 1092
Huang, C., 868
Huang, E.-S., 222, 936
Huang, J.-S., 642
Huang, J.-H., 633
Huda, S., 709
Huebner, J., 526
Hughes, C., 1155
Hughes, M. D., 28
Huneau, J.-F., 218
Hunsmann, G., 1138
Hunt, S. L., 703
Huovinen, P., 519
Hurley, J. C., 471
Husch, B., 1407
Hutcheson, R. H., 77
Hwang, C., 919
Hwang, L.-H., 633, 638
Hwang, S.-C., 638
Icenogle, J. P., 1108
Ilter, O., 704
Ilunga, M., 296
Imai, M., 227
Imlarp, S., 916
Imrie, A., 1346
International Pseudomonas aeruginosa Typing Study Group, 134
Isaachson, M., 912
Isbey, S., 532
Ishii, K., 620
Isibasi, A., 927
Ismail, R. B., 1183
Israelski, D., 416
Istas, A. S., 1334
Iversen, A. K. N., 722
Ivey, C. B., 1035
Jacewicz, M. S., 538
Jackson, J. J., 471
Jackson, L. A., 438
Jacobsen, G., 782
Jacobson, M. A., 289, 384
Jahkola, M., 519
Jansen, J., 739
Janus, J., 200
Jarvis, W., 1166
Jeannin, M., 696
Jennings, A. D., 512
Jenny, A. L., 814
Jensen, B. N., 1170
Jensen, F. C., 1256
Jenson, H. B., 1281
Jerse, A. E., 532
Jeyaseelan, R., Sr., 150
Jiang, X., 1364
Jiang, Z. D., 614
Jin, B., 868
Johnson, C. S., 689
Johnson, D. R., 658
Johnson, J. R., 119
Jones, R., 1407
Jordan, M. C., 1092
Julsrud, J., 485
Jungers, P., 399
Juszczyk, J., 1360
Kahenya, G., 1180
Kain, K. C., 464
Kalish, M. L., 281
Kanazawa, K., 940
Kantele, A., 1023
Kao, J.-H., 638
Kapcinska, M., 1360
Kapikian, A. Z., 1364
Kaplan, E. L., 658
Kaplan, S. L., 1393
Karpuch, Y., 912
Karthigesu, V., 1374
Kashala, O., 296, 628
Kaslow, R. A., 1332
Kasolo, F. C., 897
Kasongo, K., 296
Katz, J. B., 814
Katz, J., 1377
Katzenstein, D. A., 416, 722
Katzman, M., 722
Kauffmann, R. H., 1346, 1351
Kawamoto, S., 227
Kawano, S., 650
Kayembe, K., 628
Keet, I. P. M., 1236, 1244
Keitel, W. A., 477
Kelm, M. A., 1291
Kemmerly, S., 193
Kersulyte, D., 1384
Kerwar, S. S., 150
Keusch, G. T., 538
Keuter, M., 1306
Khan, A. S., 1133
Khan, M. A., 1360
Khatri, I. A., 1002
Kieny, M. P., 274
Kilani, R. T., 460
Kindt, T. J., 253
Kinoshita, M., 441

Kirstetter, M., 882
Kiviat, N. B., 793, 1284
Klein, M. R., 1236, 1244
Klein, T. W., 1177
Klenerman, P., 411
Kleyn, J., 962
Kliks, S. C., 281
Klimas, N. G., 893
Klion, A. D., 604
Klucking, S., 41
Knigge, M. F., 801
Knight, J. A., 793
Knitter, G. H., 1284
Knupp, C. A., 1250
Kobayashi, H., 683
Kobofcik, J., 686
Koehler, J., 547
Koelle, D. M., 956
Koenig, G., 653
Koerber, K. L., 184
Koev, L. A., 553
Koles, N., 553
Kolonoski P., 575
Kolson, D. L., 746
Koopmans, P. P., 1351
Koot, M., 1236, 1244
Kos, T., 1226
Koster, R., 1346
Kotler, D. P., 178
Kovacs, A., 975
Kovacs, J., 456
Kozal, M. J., 722
Krause, P. J., 923
Krause, P. R., 1084
Krebs, J. W., 1271
Kreiss, J., 754
Kremsner, P. G., 467
Kremsner, P. J., 1418
Krol, A., 1236
Kroll, J. S., 676
Krone, M., 962
Kropec, A., 526
Kropp, H., 471
Ksiazek, T. G., 1271
Kuo, C.-C., 680
Küpcü, Z., 1407
Kurawadwala, J., 1084
Kurman, R. J., 235
Lackner, A., 1116
Laga, M., 1108
Lähdeaho, M.-L., 908
Lal, R. B., 407, 496
La Montagne, J. R., 1189
Landini, M. P., 83
Landucci, G., 1377
Lane, H. C., 981
Lang, A. B., 1159
Lang, R., 912
Lange, J. M. A., 1346, 1351
Lanphear, B. P., 703
Larder, B. A., 411
Larder, B., 267
Latgé, J. P., 683
Lawler, P., 235
Lazizi, Y., 704
Leach, C. T., 766, 1281
Leal, M., 267
LeDuc, J. W., 204
Lee, J. W., 356
Lee, L. A., 547
Lee, Mei-Ling T., 127
Lefrère, F., 882
Lefrère, J.-J., 882
Lehmkuhl, H. D., 814
Lehtinen, M., 908
Leombruno, D., 1368
León, S., 1412
Leszczynski, J., 1368
Lett, S. M., 1297
Lett-Brown, M. A., 1265
Levi, M., 665
Levine, M. M., 927
Levine, P. H., 407
Levy, J. A., 281
Lew, E. A., 178
Lew, J. F., 1364
Lewis, A. P., 875
Li, E., 868
Liabakk, N.-B., 420
Liang, Y., 112
Lichtner, M., 1179
Liebman, H. A., 1250
Lien, E., 420
Lietzau, J., 9
Lin, H.-H., 638
Lin, J.-T., 229
Lin, M.-Y., 633
Linde, A., 1096
Lindo, J. F., 692
Linnemann, C. C., 703
Liu, B., 668
Liu, Z., 919
Liu, Z., 766
Loewenthal, M., 1346
Lok, A. S., 875
Longfield, J. N., 1
Looareesuwan, S., 710
Losonsky, G., 927
Lottenberg, R., 143
Loughlin, A. M., 1297
Lourida, A. N., 853
Louwagie, J., 48
Louzir, H., 1183
Loynds, B. M., 676
Lu, J. C., 936
Lubaki, N., 975
Lucero, M. G., 479
Lucht, E., 1096
Lüer, W., 1138
Lukac, V., 204
Lüke, W., 1138
Lundgren, J. D., 1170
Luo, N. P., 897
Luo, N., 614
Luppi, M., 943
Luque, F., 267
Luzzi, I., 208
Maassab, H. F., 477
Mach, M., 83
Mackiewicz, A., 1360
Maehama, T., 940
Maelankiri, L., 595
Maertens, G., 1226
Magnuson, T., 1100
Magruder, C., 1
Mahoney, D. H., Jr., 1393
Mainardi, J.-L., 1318
Maiorana, A., 943
Mäkelä, P. H., 1023
Makhlouf, L. M., 460
Mäki, M., 908
Malawista, S. E., 668
Malik, A., 927
Malin, A., 1180
Maloney, S., 1166
Mann, D. L., 1332
Mannhalter, J. W., 1407
Manoka, A. T., 1108
Manos, M. M., 235
Manzila, T., 975
Marasca, R., 943
Marchand, S., 475
Marchant, C. D., 1297
Mariotti, M., 882
Markowitz, N., 214
Marlink, R., 296
Marostenmaki, J., 1162
Marrie, T., 434
Martin, R. R., 1250
Martinelli, J., 575
Martini, F., 1175
Mascola, J. R., 48
Maslow, J. N., 526
Mason, E. O., Jr., 1393
Massias, L., 821
Mastroianni, C. M., 1179
Masur, H., 456
Mathews, J. H., 512
Mathewson, J. J., 614
Mathiesen, D., 1050
Matkin, C. C., 289
Matsaniotis, N. S., 853
Matson, D. O., 504
Matsubayashi, N., 897
Matts, J. P., 384
Mauël, J., 105
Maupin, G. O., 1271
Maurin, M., 330
May, G. L., 1151
Mayumi-Aono, A., 787
McAuliffe, T., 775
McCluer, R. H., 538
McCusker, J. H., 859
McCutchan, F. E., 48
McDonald, J. M., 1334
McElrath, M. J., 41
McGann, K. A., 746
McGlasson, D., 1356
McIver, J., 1368
McNeil, J. G., 48
McParlin, S., 1281
Meheus, A., 701
Meis, J. F., 1062
Melchers, W., 1062
Mencacci, A., 1325
Mendy, M., 1374
Meningococcal Disease Study Group, 438
Merigan, T. C., 416, 722
Mertz, G. J., 1338
Mesman, B., 1244
Meyer, W. A., III, 722
Meyers, H. B., 1133
Miailhes, P., 1417
Midkiff, B. R., 996
Miedema, F., 1236, 1244, 1351, 1408
Milazzo, M., 1
Miller, B. R., 512
Miller, C. J., 1116
Miller, J. M., 814
Mills, G. B., 1121
Mills, J., 879
Minor, P. D., 512
Mishu, B., 547, 1177
Mitchell, C. J., 512
Mitchell, P. D., 668
Mitchell, S., 847
Mitsuya, H., 9
Miyoshi, I., 620
Mobassaleh, M., 538
Mohler, J., 1318
Mølbak, K., 581
Monath, T. P., 512
Montravers, P., 821
Moore, D. F., Jr., 1419
Moreillon, Ph., 1397
Moreno, D., 1381
Moreyra, L., 754
Morishita, N., 620
Morita, T., 650
Morton, W. R., 1284
Morzunov, S., 1271
Mosci, P., 1325
Moseley, S. L., 119
Moser, C. A., 1413
Moss, R. B., 1256
Mosser, D. M., 425
Möttönen, T., 1023
Mougenot, J. F., 449
Mouginis, T., 553
Mourton, T., 1100
Moxon, E. R., 676
Mpabalwani, M., 897
Msiska, R., 1180
Mubikayi, L., 628
Mueller, S. H., 1256
Mujica, O. J., 1381
Mukeba, P., 296, 628
Mukhopadhyay, A. K., 1029
Mulder, B., 1417
Mulder, J. W., 739
Muller, E., 526, 1042
Müller, F., 420, 889
Mullin, P. D., 689
Munguia, D., 642
Murphy, C. M., 793
Murphy, D., 473
Murr, C., 224
Murray, K., 1226

Musey, L., 975
Musser, J. M., 1393
Muth, K., 384
Myers, M. G., 947
Nadelman, R. B., 1410
Nagai, S., 162
Nagamine, M., 940
Nagra, R. M., 623
Naides, S. J., 939
Nair, G. B., 1029
Nakajima, Y., 940
Nakao, M., 787
Nakashima, Y., 940
Nakayama, M., 940
Nardin, E., 927
Nassos, P. S., 289
Natanson, C., 553
Nataro, J. P., 927
Nathanson, N., 746
Navarro, A., 1412
Neaton, J. D., 384
Neifer, S., 467
Nelsing, S., 478
Nelson, J. A., 623
Nelson, K., 37
Neva, F. A., 692, 1076
Newman, B., 831
Newman, F. K., 1121
Newsom-Davis, J., 941
Newton, C., 1177
Newton, E. R., 1281
Nguyen, B.-Y., 9
Nguyen, H., 350
Ni, Y.-H., 638
Nichol, S. T., 1271
Nielsen, J. O., 478
Nielsen, T. L., 478, 1170
Niewiesk, S., 941
Nightingale, S., 941
Nightingale, S. D., 617
Noel, G. J., 425
Nolan, C. M., 189
Nolte, R. E., 260
Nopdonrattakoon, L., 595
Nord, C.-E., 1096
Noriega, F. R., 927
Nosten, F., 595
Ntakibirora, M., 1035
Ntibakivayo, M., 1035
Nugent, S. L., 1121
Numazaki, Y., 897
Nüssler, A. K., 1417, 1418
Nutman, T. B., 588, 604, 686
Nyandwi, S., 1035
Obradovic, M., 204
O'Brien, D., 402
Ogino, M. T., 491
Ojeh, C., 1002
Okuda, K., 227
Oldfield, E. C., 700
Olivola, D., 1035
Olmsted, L., 962
Oluoch-Mitchell, E., 952
Onderdonk, A., 127
Orenstein, J. M., 178
Oronsky, A. L., 150
Orskov, F., 119
Orskov, I., 119
O'Ryan, M. L., 504
Oshitani, H., 897
Oster, C. N., 1
Österblad, M., 519
Ostroff, S. M., 289
O'Sullivan, T. L., 700
Ottesen, E. A., 604, 1071
Owen, M. J., 1265
Owen, S. M., 407
Paavonen, J., 908
Paelinck, D., 1226
Pagano, J. S., 184
Pahls, S., 1057
Pais, L., 847
Pakuts, A., 1103
Palacios, A. M., 1381
Pallansch, M. A., 905, 1133
Palmer, P. S., 68
Pappas, I. G., 853
Papunen, R., 1023
Pardridge, W. M., 55
Parent, M., 526
Parker, C. E., 941
Parker, R. A., 77
Parkinson, A. J., 793
Parkkonen, P., 908
Pasatiempo, A. M. G., 441
Patel, J. A., 1265
Patton, D. L., 680
Paul, D. A., 801
Peck, A., 956
Pedersen, M., 485
Pelloux, H., 1181
Pennington, J. E., 214
Perez, G., 384
Perfumo, F., 208
Perk, Y., 704
Perlman, S., 782
Permin, H., 485
Pernod, G., 1181
Persing, D. H., 668, 1050
Peter, J., 356
Peters, C. J., 1271
Peterson, E., 41
Peterson, P. K., 1092
Petri, W. A., Jr., 483
Petrofsky, M., 575
Phadke, P. M., 686
Phair, J. P., 28
Phan, L. D., 193
Phanuphak, P., 227
Phillips, I. A., 754
Phillips, R. E., 411
Picard, B., 119
Pickering, L. K., 504
Pickett, W. C., 150
Pidcock, K. A., 1413
Piedra, P. A., 1368
Pier, G. B., 526, 1042
Pillot, J., 704
Pilot-Matias, T., 801
Pineda, J. A., 267
Piot, P., 754
Pittman, K. A., 1250
Pizzo, P. A., 356
Platt, R., 127
Plikaytis, B. D., 438, 847
Plotkin, B., 193
Pluda, J. M., 9
Plummer, W. D., Jr., 68
Podzorski, D. S., 668
Pohle, H.-D., 1138
Poles, M. A., 178
Poli, G., 975
Pollack, M., 472, 553
Pollak, P. T., 434
Polonelli, L., 1401
Pomeroy, C., 1092
Ponton, J., 1401
Poolman, J. T., 673
Poovorawan, Y., 228
Porat, R., 480
Porter, J. C., 553
Portincasa, P., 1401
Portner, A., 248
Powers, D. C., 1125
Poyart, C., 449
Prince, G. A., 1368
Prince, H. E., 1409
Prior, S., 871
Proud, D., 1007
Puccetti, P., 1325
Pukrittayakamee, S., 932
Puolakkainen, M., 908
Qadri, F., 230
Que, J. U., 1159
Quick, R. E., 1050, 1381
Quinn, F. D., 430
Quinn, T. C., 975, 990
Quint, W., 1062, 1226
Rabsch, W., 562
Race, R. E., 814
Raghavan, S., 538
Ragni, M. V., 722
Rahman, A. S. M. H., 709
Ramamurthy, T., 1029
Ramon, J., 218
Randall, T., 497
Raoult, D., 330
Räsänen, L., 1023
Rasheed, S., 722
Rasheed, S., 713
Ravasi, L., 1112
Ray, K., 1
Reed, G. W., 241
Reed, K. D., 668
Reeves, M. W., 438
Reeves, W. C., 793, 1108
Reibnegger, G., 224
Reichlin, S., 1014
Reingold, A. L., 289
Reisbrodt, R., 562
Remick, D., 214
Remington, J. S., 375
Renversez, J. C., 1181
Resti, C., 208
Revillard, J.-P., 696
Ricard, J., 1181
Rich, E. A., 18
Richards, M., 1407
Richieri, S. P., 1256
Richman, D. D., 968
Ricour, C., 449
Ries, A. A., 1035
Riley, G., 402
Riley, M. A., 402
Rimland, D., 384
Ringwald, P., 1417
Risch, P., 1166
Ritter, A., 801
Rivière, Y., 274
Rizzoni, G., 208
Roberts, B., 241
Roberts, C., 1
Roberts, P. L., 119
Robertson, M. N., 274
Robinson, M. M., 814
Robinson, R. D., 692
Roche, J. K., 170
Rockett, K. A., 1071
Rocklin, R., 1346
Rodrigue, D., 547
Roehrig, J. T., 512
Roers, A., 807
Rogers, D. E., 1201
Roggen, E. L., 754
Roingeard, P., 475, 1411
Rollin, P. E., 1271
Rolston, K. V. I., 350
Romani, L., 1325
Romero, L. I., 1014
Rongnoparut, P., 464
Rook, G. A. W., 162
Roos, M., 1236
Rosenberg, R., 464
Rosmini, F., 208
Ross, A. C., 441
Rossi, C. A., 204
Rott, O., 1142
Rubinstein, E., 218
Rudolph, D., 407
Rudolph, D. L., 496
Ruedeberg, A., 1159
Ruf, B., 1138
Rummukainen, M., 519
Rupp, M. E., 1174
Rusconi, S., 1112
Rush, B. B., 235
Rusnak, J. M., 1356
Russo, T. A., 112
Rutledge, B. J., 668
Ryan, R., 923
Rybak, M. J., 700
Ryder, R. W., 1108
Rys, P. N., 668
Sabet, S. F., 703
Sabo, A., 260
Sack, R. B., 230, 709
Sadoun-Journo, E., 449
Safrin, S., 193, 879
Sahai, J., 1103
St. Geme, J. W., III, 337, 425

St. Julien, L., 218
St. Louis, M., 975, 1108
Saito, T., 227
Sajjan, U., 1002
Saken, E., 562
Saliou, P., 399
Salom, C. L., 875
Sánchez, J., 754
Sande, M. A., 1197
Sanders, P. G., 512
Sandström, E., 1096
Saniel, M. C., 479
Sannella, E. C., 77
Sannes, M., 730
Saravolatz, L. D., 214, 384
Sarfati, J., 683
Sarisky, J., 1271
Sattabongkot, J., 464
Sauerwein, H. P., 739
Sauerwein, R. W., 157, 1306
Saville, M. W., 9
Sawada, T., 620
Sawasdikosol, S., 253
Sawyer, M. H., 91
Saxon, A., 962
Sayers, M., 1219
Schaad, U. B., 1159
Schacker, T., 37, 1342
Schaffner, A., 224, 1057
Schaffner, W., 77
Schattenkerk, J. K. M. E., 1170
Schellekens, H., 1226
Scherer, S., 1062
Scheutz, F., 581
Schieferstein, G., 223
Schielke, E., 1138
Schiffman, M. H., 235
Schipper, P., 1346
Schleimer, R. P., 1007
Schloss, M. L., 793
Schmid, D. S., 793
Schmitz, J., 449
Schneemann, M., 224
Schneider, Y.-J., 231
Schnittman, S. M., 981
Schnitzer, P. G., 793
Schoedon, G., 224
Scholten, R. J. P. M., 673
Schonberger, L. B., 1133
Schreij, G. S., 1351
Schuitemaker, H., 1408
Schultz, A. W., Jr., 1174
Schut, R. L., 1092
Schuurman, R., 1351
Schwartz, I., 1410
Schwebke, J., 962
Scott, D. R., 235
Scroggs, R. A., 248
Sebastiani, A., 1176
Sedmak, G. V., 775
Seminario, L., 1381
Seppälä, H., 519
Serra, M., 1175
Seville, P., 1346
Shafer, R. W., 722
Shanley, J. D., 1088
Shapiro, C., 990
Shapiro, E. D., 212
Shelhamer, J., 356
Shen, C.-Y., 222, 936
Sherman, M. E., 235
Sheu, J.-C., 229
Shih, C.-M., 938
Shimada, T., 1029
Shiro, H., 526, 1042
Shriver, K., 962
Shu, P.-Y., 633
Shulman, R. J., 1393
Siber, G. R., 1297, 1368
Sierra-Madero, J. G., 18
Sil, B. K., 512
Silva, A., 343
Silva, E., 1297
Silva, J., Jr., 661
Simberkoff, M. S., 893
Simpson, R. M., 253
Sims, M. J., 875
Sing, G. K., 871
Singh, N., 1406
Sisay, F., 702
Slade, H. B., 1256
Smith, D. F., 1183
Smith, J. A., 1162
Smith, J., 105
Smith, M. S., 184
Smith, T., 193
Snider, D. E., Jr., 1189
Snowder, G. D., 653
Solomon, M. A., 553
Sombrero, L. T., 479
Sorrell, T. C., 1151
Spaccapelo, R., 1325
Spector, S. A., 491
Spein, A. R., 485
Spencer, L. T., 491
Spielman, A., 923, 938, 1050
Spinola, S. M., 1146
Spiropoulou, C. F., 1271
Spooner, C., 214
Stamm, W. E., 119, 754, 793, 962, 1284
Stanberry, L. R., 947, 1084
Stapleton, J. T., 939
Starr, S., 197
Steere, A. C., 313, 1014
Stein, D. S., 28
Steinberg, S. M., 9
Stevens, D. A., 859
Stocker, S. A., 438
Stojanovic, R., 204
Stone, E. N., 289
Stout, J. E., 919
Stout, R. W., 847
Straus, S. E., 1084
Strauss, J. F., 746
Stull, T. L., 1413
Sudol, T. E., 937
Sun, C., 868
Sundqvist, V.-A., 1096
Sundsfjord, A., 485
Sundstrom, P., 452
Suwanabun, N., 464
Suzuki, H., 897
Swack, N. S., 939
Sweeney, Y. T. C., 680
Swenson, P., 962
Swierkosz, E. M., 1121
Syrogiannopoulos, G. A., 853
Sztein, M. B., 927
Sztelma, K., 1151
Tabet, S. R., 189
Tabor, E., 706
Tacket, C. O., 927
Taffs, F., 512
Takala, A., 337
Takeda, T., 1029
Takeda, Y., 1029
Takei, H., 940
Talbot, J. A., 1291
Tamura, K., 916
Tamura, M., 200
Tan, T. Q., 1393
Tanaka, Y., 620
Tang, Y. J., 661
Tangkitchot, S., 595
Tanner, P. M., 703
Tao, H., 568
Tatro, J. B., 1014
Tauxe, R. V., 547, 1035, 1381
Tebourski, F., 1183
Tedesco, L., 919
Telford, S. R., 568
Telford, S. R., III, 923, 1050
ten Cate, H., 665
ten Cate, J. W., 665
Ten Napel, C. H. H., 1351
Tenover, F. C., 438, 1035
Teo, C. G., 62
Terada, K., 650
ter Kuile, F., 595
Terry, S. I., 692
Terry Beirn Community Programs for Clinical Research on AIDS, 384
Theodoridou, M. C., 853
Thole, J. E. R., 162
Thomas, D. D., 445
Thomas, D. L., 990
Thomas, H. C., 875
Thomford, J. W., 923, 1050
Thompson, C. M., 1368
Thompson, J., 200
Thompson, J. M., 241
Thursz, M., 875
Tieamboonlers, A., 228
Tilles, J. G., 1377
Tipping, D., 1256
Todd, C. W., 1297
Tognon, M., 1175
Tolan, R. W., Jr., 1384
Toltzis, P., 1100
Tompkins, R. G., 95
Tonawanda/Williamsville Pediatrics, 1312
Tonta, A., 1112
Toomey, K. E., 793
Toossi, Z., 18
Torelli, G., 943
Torley, L. W., 150
Torok-Storb, B., 769
Torres, P.-J., 1390
Torres, Y., 267
Tosteson, T. D., 1042
Totten, P. A., 1284
Traavik, T., 485
Tran, P.-O. T., 658
Trauger, R., 1256
Treanor, J., 402
Trifillis, A. L., 831
Trnka, Y., 127
True, C. A., 939
Tsai, C.-C., 260
Tsiquaye, K., 1226
Tungtaem, C., 916
Turner, P. F., 1071
Turner, R. W., 1138
Uchida, T., 1265
Ugurlu, M., 704
Uhlén, M., 611
Urban, M., 83
Utsalo, S. J., 831
Utt, E. A., 430
Uttley, A., 1180
Vadhan-Raj, S., 1419
Valdesuso, J., 1364
Valentine, F. T., 28, 1250
Valkenburg, H. A., 673
van Belkum, A., 1062
van Dalen, R., 157
van der Ende, I., 1346
van der Ende, M. E., 1351
van der Meer, J. W. M., 157, 1306
van der Poll, T., 665, 739
van der Ven-Jongekrijg, J., 157, 1306
van Deuren, M., 157
van Deventer, S. J. H., 665, 739
van Doorn, L.-J., 1226
Vanijanonta, S., 932
Vannice, J. L., 157
van Zanten, S. J. O. V., 434
Vargas, R., 1381
Velimirovic, D., 204
Verdier, M., 225
Vergara, J. A., 395
Vernon, S. D., 1108
Vesikari, T., 1364
Veugelers, P., 1236
Vila, J., 1390
Vinluan, A., 703
Vire, D., 1
Virtanen, E., 1023
Visscher, B. R., 766
Vissers, M. C. M., 839
Vitt, C. R., 369
Vittinghoff, E., 289
Voeller, D. M., 456, 1414
Voermans, J., 1226
Vogel, P., 692

Vogel, S., 981
Vogel, U., 562
Volberding, P., 713
Volberding, P. A., 28
Vullo, V., 1179
Vuong, C., 642
Vuo' .o-Varkila, J., 519
Wachter, H., 224
Wagner, K. F., 48
Wahlberg, J., 611
Wahlquist, S. P., 1035
Wahren, B., 1096
Walawander, C. A., 1250
Wallace, M. R., 91, 700
Wallace, R., Jr., 1166
Walsh, E. E., 1368
Walsh, T. J., 356
Wang, H., 143
Wang, J.-T., 229
Wang, M., 868
Wang, R., 623
Wang, T.-H., 229
Ward, R. L., 900
Warren, H. S., 95
Warren, J. W., 831
Waters, M., 162
Watson, A. S., 248
Watson, B., 197
Weaver, R. E., 438
Weber, T., 1138
Wedgwood, J., 1159
Weigel, H. M., 1346, 1351
Weisman, L. E., 324
Weiss, G., 224
Weiss, S. H., 1080
Weissbach, N., 193
Welbel, S., 1166
Wells, J. G., 1035
Wenger, J. D., 438, 847
Wenisch, C., 710
Wenman, W. M., 460
Wentworth, D. N., 384
Werner, E. R., 224
Werner-Felmayer, G., 224
Westblom, T. U., 996
Wested, N., 581
Westrich, M. K., 68
Wetterlow, L. H., 1297
Weverling, G. J., 739
Weverling, G. J., 1351
Weyant, R. S., 430
Whaley, K. J., 647
Wherry, J. C., 214
Whicker, L., 532
Whitby, J. E., 512
Whitby, S. N., 512
White, N. J., 595, 932
Whittle, H. C., 1374
Wick, M. M., 150
Wild, L. M., 1146
Wiley, C. A., 623, 642
Wiley, E. L., 617
Willems, B., 473
Williamson, W. D., 1334
Willson, R., 1219
Wilson, J., 1219
Wilson, K. H., 305
Wilson, M., 923
Wilson, S. R., 324
Winger, E., 416
Winkler, S., 467
Winkler, T., 83
Winograd, M., 689
Winterbourn, C. C., 839
Winters, M. A., 416, 722
Wirtz, R. A., 464
Wissner, A., 150
Wolfe, W. H., 847
Wolff, S. M., 480
Wong, A., 1162
Wood, D. J., 512
Wood, J., 875
Woods, J. P., 1384
Worley, M., 430
Wormser, G. P., 1410
Wright, P. F., 68, 77, 200, 241
Wu, C.-W., 222, 936
Wu, Y. N., 91
Wyvill, K. M., 9
Xiao, S.-Y., 204
Xu, K., 296
Yajko, D. M., 289
Yamashiro, T., 940
Yang, J., 55
Yang, S.-L., 222, 936
Yang, Y.-S., 222
Yap-Yap, J., 1417
Yarchoan, R., 9
Yatsiv, I., 553
Yeh, S.-H., 638
Yeh, T.-S., 936
Yolken, R. H., 1002
York, J., 1409
Yoshihiro, K., 650
Young, L. S., 575
Yu, V. L., 919, 1406
Yusof, J. H. M., 62
Yuwen, H., 706
Zang, G.-L., 936
Zangwill, K. M., 847
Zartarian, M., 1377
Zeh, J. E., 37
Zeitlin, L., 647
Zhang, T., 235
Zhang, Y., 1166
Zhou, X. Y., 1318
Ziegweid, K., 956
Zimmerman, P. A., 686
Zimmerman, R. J., 369
Zolla-Pazner, S. B., 893
Zoumboulakis, D. J., 853
Zu, S., 170
Zumla, A., 614, 897

# Subject Index


$\alpha$-$_1$acid glycoprotein glycoforms, in HIV-1 infection, 1360
Acyclovir for
  CMV prophylaxis, liver transplant recipients, 1406, 1407
  HSV infection
    neonatal, guinea pig model, 947
    recurrence and resistance after prolonged treatment, 1338
Adenovirus, disease, incidence in bone marrow transplant recipients, 775
Adherence, *Borrelia* species, in vitro model, 445
AIDS (*See also* human immunodeficiency virus type 1)
  *E. bieneusi* intestinal disease in, albendazole for, 178
  response in US, IDSA meeting presentation, 1201
Albendazole, for *E. bieneusi* intestinal disease, in AIDS, 178
Amebiasis, host-parasite relationships, 483
Amikacin, bactericidal activity, against *S. aureus*, 330
Aminoglycosides, for *K. pneumoniae* endocarditis, rabbit model, 1318
Amoxicillin, for *S. sanguis* endocarditis, 1397
Amphotericin B, liposomal
  for aspergillosis, invasive pulmonary, 356
  against *C. albicans*, mouse model, 1057
Animal model
  bacteremia, gram-negative, cellular distribution of endotoxin, rat, 95
  *B. burgdorferi*, protective immunity, mouse, 568
  *C. albicans* infection
    amphotericin B for, liposomal, mouse, 1057
    M-CSF for, rat, 369
    soluble IL-4 receptor for, mouse, 1325
  ciprofloxacin, intestinal elimination, rat, 218
  CMV infection, TNF$\alpha$ role, mouse, 1088
  *C. trachomatis*, salpingitis, delayed hypersensitivity, monkey, 680
  *E. coli*, septic shock, MAb function, dog, 553
  *E. faecalis*, role in experimental peritonitis, rat, 821
  *G. muris*, antigen, recognized by intestinal IgA, mouse, 395
  group A streptococcal pharyngeal infection, passive protection by lipoteichoic acid, mouse, 319
  HCV infection, longitudinal analysis and genetic drift, chimpanzee, 1226
  *H. ducreyi*, infection, primate, 1284
  HIV-1, in monocytes, chimpanzee, 1407, 1408
  HSV infection
    encephalitis, after trigeminal nerve inoculation, mouse, 782
    genital, latency-associated transcript, 1084
    neonatal, pathogenesis and treatment, guinea pig, 947
  HSV-2, immunization, passive topical, mouse, 647
  HTLV-II, immunoglobulin prophylaxis, rabbit, 620
  *K. pneumoniae*, endocarditis, isepamicin and aminoglycosides for, rabbit, 1318
  *M. avium* complex, infection, effect of GM-CSF on antibiotic action, mouse, 575
  *S. aureus*, sepsis, CL 184,005 for, mouse, 150
  *S. epidermidis*, endocarditis, virulence, rabbit, 1042
  SIV infection
    intestinal lymphoid tissue, rhesus macaque, 1116
    treatment, macaque, 260
  *T. gondii*, encephalitis, SCID mouse model, 375
  *V. cholerae* O139 Bengal, diarrhea, lack of protective immunity, rabbit, 230
  *Y. enterocolitica*, virulence, desferrioxamine-promoted, mouse, 562
Antibody to
  *B. burgdorferi*, in European Lyme borreliosis, 313
  *B. microti*, diagnostic test, 923
  CMV, in HIV-1 infection, 1096
  *C. parvum*, in AIDS, 696
  *C. trachomatis*, in infants, 908
  dihydropteroate synthetase, 1414
  HIV-1 envelope protein, 274, 281
  hsp on HTLV-I–infected cell lines, 253
  influenza A virus, in children, 200
  *L. donovani infantum* hsp 70, 1183
  measles virus, 1377
  *M. leprae* protein antigen 85B, 162
  *N. meningitidis* polysaccharide vaccine, 847
  rex, in HTLV-I infection, 496
  rotavirus, in children, 504
  RSV, neutralizing, 1368
  *S. epidermidis*, opsonic, 324
  *S. pneumoniae*, LPS-enhanced response, 441
  tax, in HTLV-I infection, 496
Aspergillosis, pulmonary, invasive, amphotericin B for, 356
*Aspergillus fumigatus*, DNA typing, 683

*Babesia microti*, antibody, diagnostic test, 923
*Bacillus*, gastroenteritis, 703
Bacteremia
  gram-negative
    cellular distribution of endotoxin, 95
    priming of circulating PMNL, 1151
  gram positive, in cancer, vancomycin vs. teicoplanin for, 350
  MAC, risk in HIV-1 infection, 289
  *S. epidermidis*, nosocomial transmission, neonatal, 526
Bactericidal/permeability-increasing protein, recombinant, inhibition of nitric oxide synthesis, 105
Bacteriuria, asymptomatic, screening in pregnancy, to prevent pyelonephritis, 1390
BK virus, and HIV-1 infection, 485
Bone marrow transplantation
  adenovirus disease, incidence, 775
  CMV envelope glycoprotein genotypes, 769
*Bordetella pertussis*, infection and vaccine efficacy, 1981–1991, 1297
*Borrelia burgdorferi*
  antibody, in European Lyme borreliosis, 313
  detection
    in blood, 1410
    by PCR, 668
  immunity, protective, 568
  infection, ceftriaxone for, in children, 937, 938
  LPS, effect on nitric oxide and IL-6 production, in rat brain cells, 1014
*Borrelia* species, adherence, in vitro, 445
Brazilian purpuric fever, *H. influenzae*, biogroup aegyptius, in vitro model, 430

C5a, binding to neutrophils, due to endotoxin, 480
*Campylobacter jejuni*, HIV-1 infection, and Guillain-Barré syndrome, 1177
Cancer, vancomycin vs. teicoplanin for gram-positive bacteremia, 350
*Candida albicans*
  characterization, fluconazole-treated neutropenic patients, 1062
  infection
    amphotericin B for, liposomal, 1057
    heat-shock mannoproteins and sIgA, 1401
    M-CSF for, rat model, 369
    soluble IL-4 receptor for, 1325
  protein, in culture supernatants, 452
Carcinoma, hepatocellular, and HCV nucleotide sequence, 706

CD28, expression, in HIV-1 infection, 730
CD4 lymphocyte
depletion, in chronic delta virus infection,475
in HIV-1 infection
recombinant soluble, effect on viremia, 37
variation, within-subject, 28
Ceftriaxone, for *B. burgdorferi* infection, in children, 937, 938
Cervical infection and dysplasia, HPV, prevalence, 792
Chancroid
human, experimental, 1146
primate model, 1234
*Chlamydia trachomatis*
pneumonitis, in infants, antibody response, 908
salpingitis, delayed hypersensitivity, monkey model, 680
Chloroquine or quinine, and clindamycin, for *P. falciparum* malaria, 467
Cholera, epidemic, role of produce in risk and prevention, 1381
Ciprofloxacin, intestinal elimination, rat model, 218
Clindamycin, and chloroquine or quinine, for *P. falciparum* malaria, 467
*Clostridium difficile*
diarrhea
community-acquired, 127
and pseudomembranous colitis, therapy, 1291
genotypes, 661
Colony-stimulating factor, in candidiasis, rat model, 369
Crohn's disease, *M. paratuberculosis*, detection by PCR, in children, 449
*Cryptosporidium parvum*
coproantigens, 460
IgA antibody, in AIDS, 696
infection, intestinal epithelium, in vitro model, 170
Cystic fibrosis, influenza vaccines in, 241
Cytokine production
in HIV-1–infected macrophages, 18
and plasma levels, in meningococcal infection, 157
Cytomegalovirus
antibodies, in HIV-1 infection, 1096
in CSF of AIDS patients, detection by PCR and ELISA, 623
DNA, in CSF of neonates with congenital infection, 1334
envelope glycoprotein genotypes, distribution in bone marrow recipients, 769
IgG subclass distribution, 83
infection
in liver transplant recipients, acyclovir prophylaxis for, 1406
maternal, and maternal age, 936
in semen, 222, 223, 766
TNFα role, mouse model, 1088
replication, in microglia, effect of IFN-γ, 1092

D-mannitol, to detect *A. fumigatus*, in bronchiolar lavage, 356
Dapsone, and sulfonamides, as inhibitors of *P. carinii* dihydropteroate synthase, 456
Deferoxamine, effect on zygomycetes, 231
Delayed-type hypersensitivity skin tests, as predictor of HIV-1 progression, 893
Delta antigenemia, in chronic delta virus infection, 475
Desferrioxamines, effect on yersiniosis, 562
Diarrhea
acute
and chronic, in HIV-1 infection, 614
HIV-1 and rotavirus infections, in children, 897
*C. difficile*, community-acquired, 127
childhood, in Guinea-Bissau, 581
demography to pharmacology, IDSA meeting presentation, 1206
etiology, in rural Western Thailand, 916
*Shigella*, pathogenesis, 538
*V. cholerae* O139 Bengal, lack of protective immunity, 230
Didanosine
pancreatitis, in AIDS, risk, 1250
and zidovudine, for HIV-1 infection, 9, 416, 722
Diethylcarbamazine, for loiasis, 604
Dihydropteroate synthase
antibodies, 1414
*P. carinii*, inhibition by sulfonamides and dapsone, 456
DNA, VZV, detection in air samples, 91
*Echinococcus multilocaris*, infection, alveolar, HLA-DR13 and susceptibility, 1416
Echovirus 30, infection, meningitis, in child care center, 1133
Editorial
HTLV-II, epidemiology, 1080
MHC, role in HIV-1 infection, 1332
ELISA, antigen capture, to detect CMV DNA, in CSF, in AIDS, 623
Encephalitis
HSV, after trigeminal nerve inoculation, mouse model, 782
*T. gondii*
pyrimethamine, prophylaxis, in AIDS, 384
SCID mouse model, 375
yellow fever vaccine, 512
Endocarditis
*K. pneumoniae*, isepamicin and aminoglycosides for, rabbit, 1318
*S. epidermidis*, virulence, 1042
*S. sanguis*, amoxicillin for, 1397
Endotoxemia, induction of IL-1 receptor antagonist, 665
Endotoxin
cellular distribution, after LPS injection, 95
*E. coli*, antibiotic influence on release, 471, 472
low-dose, effect on C5a binding by neutrophils, 480
Enolase, *C. albicans*, 452
*Entamoeba dispar*, nonpathogenic, 483
*Entamoeba histolytica*, host-parasite relationships, 483
*Enterococcus faecalis*, role in experimental peritonitis, 821
*Enterocytozoon bieneusi*, intestinal disease in AIDS, albendazole for, 178
Enterovirus 71 infections, 1977–1991, 905
Enzyme-linked immunospot assay, to detect antibody-secreting cells, in UTI, 1023
Epidemiology
adenovirus disease, incidence in bone marrow transplant recipients, 775
*B. pertussis* infection and vaccine efficacy, 1981–1991, 1297
*C. difficile*–associated diarrhea, 127
cytomegalovirus, infection in semen, risk of AIDS, 766
diarrhea
childhood, in Guinea-Bissau, 581
etiology, in rural Western Thailand, 916
*E. multilocaris*, infection, alveolar, HLA-DR13 and susceptibility, 1416
echovirus 30, infection, meningitis, aseptic, in child care center, 1133
enterovirus 71 infections, 1977–1991, 905
HAV outbreak, immunization of high-risk susceptible subjects, 228
HBV
activation in HIV-1 infection, in Africa, 628
transmission
analyzed by PCR–single-stranded DNA conformation assay, 62
maternal to fetus, 704
HCV
genotyping, from 5′ coding region sequences, 473
perinatal transmission, maternal viremia role in, 638
hemolytic uremic syndrome, outbreak, association with *E. coli*, 208
HEV, seroprevalence, by recombinant fusion proteins and peptides, 801

HFRS outbreak, association with Puumala virus, 204
*H. influenzae* type b, meningitis, 3-year study, 912
HIV-1 infection
or ARC, didanosine pancreatitis, risk, 1250
asymptomatic, in men with low CD4 cell counts, 1236
heterosexual transmission, association with zidovudine resistance, 411
HLA and pathogenesis, homosexual cohort, 1250
HPV in, 1108
and HTLV infection, association with leprosy, 296
JC and BK virus, prevalence, 485
occupational exposure, 478
and rotavirus infections, association in children with acute diarrhea, in Zambia, 897
transmission, look-back investigation, 1
HPV, cervical infection and dysplasia, prevalence, in Alaska Native women, 792
*H. pylori*
penicillin-resistant, prevalence in US, 438
prevalence, association with age, 434
HTLV-I infection
among IVDU, 962
in sex workers, in Peru, 754
HTLV-II infection
among IVDU, 962
seroprevalence in Africa, 225
lentivirus, ovine, prenatal transmission, maternal risk factors, 653
leprosy, association with HIV-1 and HTLV, 296
*M. abscessus*, pseudoinfection, endoscope as source, 1166
*M. catarrhalis*, otitis media risk, in children, 1312
*M. leprae*, infection, association with HIV-1 and HTLV, 296
*M. tuberculosis* infection detected by
Aplisol, false-positive rate, 703
RFLP analysis, in HIV-infection, in outbreak, 189
mumps, transmission in vaccinated subjects, 77
*N. meningitidis*
meningitis, 3-year study, 912
outbreak, strain typing by PCR, 1384
norwalk virus, infection, detection in children, 1364
onchocerciasis, immunity, in Ecuador, 588
rotavirus, and HIV-1 infections, association in children with acute diarrhea, in Zambia, 897
*S. dysenteriae* type 1, panresistance and prevention, in Burundi, 1035
*S. enteritidis*, outbreaks in US, 547
*S. epidermidis*, bacteremia, nosocomial transmission, neonatal, 526
*S. pneumoniae*, infection
invasive, serotypes, in children, 212
meningitis, 3-year study, 912
*S. stercoralis*, and HTLV-I infections, immunoepidemiologic study, 692
*T. pallidum*, infection, and pregnancy outcome, in West Africa, 701, 702
tuberculosis, control in Zambia, 1180
*V. cholerae* O139 Bengal, in India, 1029
VZV, nosocomial, detection in air samples, 91
Errata
Aukrust et al., 1994;169:420–4, 1186
Badaró and Johnson, 1993;167(suppl):S13–7, 233
Piazza et al., 1992;166:1422–4, 482
*Escherichia coli*
capsular polysaccharide and pathogenesis, 112
cellular distribution after infection, rat model, 95
endotoxin, antibiotic influence on release, 471, 472
internalization into kidney epithelial cells, 831
LPS, effect on nitric oxide and IL-6 production, in rat brain cells, 1014
non-O157, outbreak of HUS, 208
septic shock, MAb function, dog model, 553
virulence, in urosepsis, by serotype, 119

Flavivirus, yellow fever vaccine, 512
Fluconazole, effect on zidovudine, in HIV-1 infection, 1103
Foscarnet, resistance, in HSV infection, in AIDS, 193

Galactomannan, as marker of aspergillosis, 356
Gastroenteritis, *Bacillus*, 703
*Giardia muris*, antigen, recognized by intestinal IgA, 395
Glycolipid, as receptor for Shiga toxin, 538
Gram-positive sepsis, PAF antagonist for, 150
Granulocyte-macrophage colony-stimulating factor, for MAC infection, mouse model, 575
Group A streptococci
epidemiologic typing, 519
M protein presence, 658
plasminogen receptors, 143
Guillain-Barré syndrome, *C. jejuni* infection, and HIV-1 infection, 1177

*Haemophilus ducreyi*, infection
experimental, in humans, 1146
primate model, 1284
*Haemophilus influenzae*
biogroup aegyptius, Brazilian purpuric fever, in vitro model, 430
macrophage binding, 425
meningitis, dexamethasone for, in children, 853
nontypeable, capsule genes, 337
type a, virulence mutation, 676
type b, meningitis, epidemiology, 912
Hantavirus, new, *P. maniculatus* as primary rodent reservior, 1271
Health care reform, IDSA Presidential Address, 1197
Heat-shock proteins, expression on HTLV-I–infected cell lines, 253
*Helicobacter pylori*, prevalence, association with age, 434
Hemolytic uremic syndrome, outbreak, *E. coli*, 208
Hemorrhagic fever with renal syndrome
outbreak, association with Puumala virus, 204
pathogenesis and cellular immunity, 868
Hepatitis A virus
outbreak, immunization of high-risk susceptible subjects, 228
vaccine, inactivated, safety and immunogenicity, 996
Hepatitis B surface antigen–specific CTL, in asymptomatic carriers, 633
Hepatitis B virus
activation, in HIV-1 infection, 628
in bone marrow stromal cells, persistence and hematopoiesis, 871
chronic infection
HCV RNA titers in, 1411
hepatitis C, HIV infection, and syphilis, seroprevalence among non-IVDU STD clinic patients, 990
IFN-$\alpha$2a therapy for, genotype analysis, 875
transmission
analyzed by PCR–single-strand DNA conformation assay, 62
maternal to fetus, 704
vaccine
breakthrough infections and viral variant, in immunized children, 1374
response, in chronic uremia, 399
Hepatitis C virus
genotyping, from 5′ coding region sequences, 473
infection
hepatitis B, HIV infection, and syphilis, seroprevalences among non-IVDU STD clinic patients, 990

longitudinal analysis and genetic drift, 1226
perinatal transmission, maternal viremia role in, 638
nucleotide sequence, and hepatocellular carcinoma, 706
RNA levels
assessment by PCR, 1219
in chronic HBV infection, 1411
Hepatitis E virus infection
and posttransfusion hepatitis, 229
seroprevalence, by recombinant fusion proteins and peptides, 801
Herpes, genital, immunization, passive topical, 647
Herpes simplex virus
infection
encephalitis, after trigeminal nerve inoculation, mouse model, 782
foscarnet-resistant, in AIDS, 193
neonatal, pathogenesis and treatment, guinea pig model, 947
recurrence and resistance after prolonged acyclovir, 1338
susceptibility, rapid test for, 879
transcript, latency-associated, and recurrent genital infection, 1084
type 2
genital lesions, recovery of T lymphocyte clones, 956
immunization, passive topical, 647
infection, immunotherapy with adjuvant-free glycoprotein D–IL-2 fusion protein, 787
Herpes zoster, after chickenpox in infancy, 650
Histamine, production, in otitis media, 1265
HLA frequencies, and HIV-1 pathogenesis, 1250
Human herpesvirus 6
DNA, in blood cells of HIV-1–infected men, correlation with CD4 cell counts, 1342
infection
in brain tissue, human, 943
genital tract, female, 1281
Human immunodeficiency virus type 1
envelope protein, cell-mediated cytotoxic responses, 274
envelope subtype, in isolates from Romanian children, 281
envelope vaccines, response, 41
in monocytes, chimpanzee, 1407, 1408
in placental cell cultures, productive infection of macrophages, 746
and polyomaviruses, 485
infection
$\alpha_1$-acid glycoprotein glycoforms, 1360
acute and chronic diarrhea in, 614
or ARC, didanosine pancreatitis, risk, 1250
asymptomatic
immunotherapy, 1256
in men with low CD4 cell counts, 1236
CD4 cell variation, within-subject, 28
CD28 expression, 730
and *C. jejuni* infection, and Guillain-Barré syndrome, 1177
CMV antibodies in, 1096
and CMV infection of semen, risk of AIDS, 766
delayed-type hypersensitivity skin tests, as predictor of progression, 893
didanosine and zidovudine for, drug resistance mutation, 722
fluconazole effect on zidovudine, 1103
foscarnet-resistant HSV, 193
hepatitis B activation in, 628
hepatitis B, hepatitis C, and syphilis, seroprevalences among non-IVDU STD clinic patients, 990
heterosexual transmission, association with zidovudine resistance, 411
HHV-6 DNA in, 1342
HLA and pathogenesis, 1250
HPV in, 1108
and HTLV infection, association with leprosy, 296
ICAM-1 in, 1176
IFN-$\alpha$2b, and IL-2 for, 981
MHC role, 1332
nevirapine and zidovudine, alternating treatment, 1346
parvovirus B19 anemia in, 938, 939
perinatal, TNF$\alpha$ levels in neonatal plasma, 975
phenotypes in children, 491
progression, 617
provirus copy number as predictor of progression, 882
provirus load in zidovudine-treated patients, 267
risk of MAC bacteremia, 289
and rotavirus infections, association in children with acute diarrhea, 897
RPR tests, false-positive, relation to anti-cardiolipin antibody and immunoglobulin levels, 1356
sTNF$\alpha$ receptors as predictors of disease progression, 739
syncytium-inducing phenotype, impact on disease progression, 968
TNF$\alpha$ and sTNF receptors, 420
transmission, look-back investigation, 1
and visceral leishmaniasis, mononuclear cells in, 707
1,25 vitamin D serum concentration in, 889
zidovudine
and didanosine for, 9
and IFN-$\alpha$ vs. zidovudine monotherapy for, 1351
for, p24 antigen level as intermediate end point, 713
infectious particles, method to detect cell membrane proteins on, 886
neutralization serotypes, 48
occupational exposure, 478
quantitation, after didanosine and zidovudine, 416
replication, enhanced inhibition, 55
viral load in macrophages, cytokine production, and clinical status, 18
viremia, soluble recombinant CD4, effect, 37
V3 region, amino acid sequence, 227
zidovudine resistance, 184, 611
Human papillomavirus, type-specific, persistence among cytologically normal women, 235
Human T cell leukemia virus
type I infection
antibody to hsp, 253
and tropical spastic paraparesis, 941
type II, seroprevalence in Africa, 225
Human T cell lymphotropic virus infection
epidemiology, among IVDU, 962
in sex workers, in Peru, 754
type I vs. type II, lymphocyte subset patterns, 1409
type I–associated myelopathy, immune response to tax and rex, 496
type II
epidemiology, editorial, 1080
glycoprotein, sequence variation, 407
immunoglobulin prophylaxis, rabbit model, 620

IDSA meeting presentation
AIDS response in US, 1201
diarrheal diseases, 1206
health care reform, 1197
IgA
intestinal; mouse, to *G. muris*, 395
secretory
to *C. parvum*, in AIDS, 696
against HIV-1, 614
IgG, response to human CMV envelope components, 83
Immunoglobulin, prophylaxis against HTLV-II, 620
Influenza A virus, infection, primary, antibody response, in children, 200

Influenza B virus, vaccine, cold-adapted, in high-risk adults, 402
Influenza virus
  proteins, effect on PMNL respiratory burst, 1129
  vaccine
    cold-adapted, inactivated, efficacy, 68
    cold-recombinant, trivalent, in children, 1121
    heterologous, effects of aging on response, 1125
    live attenuated and inactivated, comparison in CF patients and families, 241
Intercellular adhesion molecule-1, circulating, in HIV-1 infection, 1176
Interferon, type 1, MxA as marker, in viral infections, 807
Interferon-α, and zidovudine, vs. zidovudine monotherapy, for HIV-1 infection, 1351
Interferon-α2, genotype analysis, in chronic hepatitis B patients, with IFN-α2a therapy, 875
Interferon-α2b, and IL-2, for HIV-1 infection, 981
Interferon-γ, for CMV infection, 1092
Interleukin-1
  receptor antagonist, induction by TNF and endotoxin, 665
  in rhinovirus colds, 1007
Interleukin-1α, effect on oral granulocytes and epithelial cells, 1419
Interleukin-1–receptor antagonist, in meningococcal infection, 157
Interleukin-2, and IFN-α2b, for HIV-1 infection, 981
Interleukin-4, soluble receptor, for murine candidiasis, 1325
Interleukin-6
  in *T. gondii* infection, 1181
  and TNF, role in adverse reaction after DEC treatment for filariasis and onchocerciasis, 1071
Interleukins, in typhoid fever, 1306
Isepamicin, for *K. pneumoniae* endocarditis, rabbit model, 1318
Isoniazid, resistance in *M. tuberculosis*, catalase-peroxidase mutant, 1162
Ivermectin, vs. thiabendazole, for strongyloidiasis, 1076

JC virus, and HIV-1 infection, 485

*Klebsiella pneumoniae*, endocarditis, isepamicin and aminoglycosides for, rabbit model, 1318

*Legionella pneumophila*
  eradication from hospital water system, copper-silver ionization, 919
  resistance, effect of tetrahydrocannabinol, 1177
*Leishmania donovani infantum*, antibody to hsp 70, 1183
Leishmaniasis, visceral, antibody to hsp 70, 1183
Lentivirus, ovine, prenatal transmission, maternal risk factors, 653
Lipopolysaccharide
  *B. burgdorferi*, effect on nitric oxide and IL-6 production, in rat brain cells, 1014
  binding to macrophages, inhibition by recombinant bactericidal/permeability-increasing protein, 105
  *E. coli*, effect on nitric oxide and IL-6 production, in rat brain cells, 1014
Lipoteichoic acid, as passive protection, for group A streptococcal pharyngeal infection, mouse model, 319
Liver transplants, acyclovir prophylaxis for CMV infection, 1406, 1407
Loiasis, diethylcarbamazine for, 604
Lyme disease
  antibody response, 313
  immunity, protective, 568
  pathogenesis, 668

M protein, of group A streptococci, 658
Macrophage
  alveolar, in HIV-1 infection, 18
  HIV-1 infection of, 617, 746
  human vs. murine, 224
Major histocompatibility complex, in HIV-1 infection, 1332
Malaria
  mefloquine for, in pregnancy, 595
  *P. falciparum*
    chloroquine or quinine for, and clindamycin, 467
    soluble vascular adhesion molecule 1, 710
  *P. vivax*
    circumsporozite protein polymorphs, 464
    primaquine for, in blood stage, 932
Mannoproteins, heat-shock, *C. albicans*, and sIgA, 1401
Mantoux test, to detect *M. tuberculosis*, 1174
Measles, specific antibody response and viremia, 1377
Mefloquine, malaria prophylaxis, in pregnancy, 595
Meningitis
  *H. influenzae*, dexamethasone for, in children, 853
  *N. meningitidis*, dexamethasone for, in children, 853
Monoclonal antibody to
  O polysaccharide and core regions of *E. coli* LPS, 553
  TNFα, safety and pharmacokinetics, 214
*Moraxella catarrhalis*, otitis media risk, in children, 1312
Mucins, intestinal, effect on rotavirus replication, 1002
Mumps, transmission in vaccinated subjects, 77
MxA gene expression, as marker of IFN in viral infections, 807
*Mycobacterium abscessus*, pseudoinfection, endoscope as source, 1166
*Mycobacterium avium* complex
  infection
    effect of GM-CSF on antibiotic action, mouse model, 575
    in HIV-1 infection, 617
  molecular phylogeny, 305
  in respiratory or intestinal tract, risk of bacteremia, 289
*Mycobacterium celatum*, molecular phylogeny, 305
*Mycobacterium leprae*
  infection, association with HIV-1 and HTLV, 296
  protein antigen 85B, B cell epitopes, 162
*Mycobacterium paratuberculosis*, detection by PCR, in Crohn's disease, 449
*Mycobacterium tuberculosis*
  detection by
    Mantoux test, 1174
    RFLP analysis, in HIV-infected patients, in outbreak, 189
  infection
    control, in Zambia, 1180
    detected by Aplisol, false-positive rate, 703
    Third World Congress Report, 1189
    isoniazid-resistant, catalase-peroxidase mutant, 1162

*Neisseria gonorrhoeae*, urethritis, infection, experimental, 532
*Neisseria meningitidis*
  evolution of new clones, 673
  infection
    cytokine pattern and production, 157
    outbreak, 1384
    meningitis
      dexamethasone for, in children, 853
      epidemiology, 912
    penicillin-resistant, prevalence in US, 438
    vaccine, polysaccharide, antibody response, 847
Neopterin
  antimicrobial effect, 224
  in *P. carinii* pneumonia, 1170
Neurocysticercosis, praziquantel and anticonvulsants for, 689
Neutrophil
  C5a binding, due to endotoxin, 480
  killing, in hypertonic environments, 839

Nevirapine, and zidovudine, alternating treatment for HIV-1 infection, 1346
Nitric oxide
in malaria, cerebral, 1417
synthase
biochemistry, cofactor, 224
inhibition in gram-negative sepsis, 343
synthesis, inhibition by recombinant bactericidal/permeability-increasing protein, 105
Nitrite and nitrite levels, in *P. falciparum* and *P. vivax* malaria, 1418
Norwalk virus, infection, detection in children, 1364
Nucleosides, antiretroviral, cytotoxicity, embryonic, 1100

2′-5′-oligoadenylate synthetase, serum, and response to IFN-$\beta$ in genital HPV infection, 1112
*Onchocerca volvulus*
immunity, in Ecuador, 588
infection
DEC for, TNF and IL-6 role in adverse reaction, 1071
PCR for diagnosis, 686
Onchocerciasis, immunity, in Ecuador, 588
Otitis media
acute, histamine production in, 1265
*M. catarrhalis* association, in children, 1312

P glycoprotein, expression, induced by *S. typhimurium*, 760
p24 antigen, level, in HIV-1 infection, to evaluate zidovudine therapy, 713
Pancreatitis, didanosine, in AIDS, risk, 1250
Papillomavirus, human
cervical dysplasia, prevalence, 792, 940
genital infection, IFN-$\beta$ for, 2′-5′-oligoadenylate synthetase levels, 1112
in HIV-1 infection, 1108
Parainfluenza virus type 1, human, antigenic and genetic stability, 248
Parvovirus B19, anemia, in HIV-1 infection, 938, 939
Penicillin, resistance in *N. meningitidis*, prevalence, 438
Peritonitis, experimental, *E. faecalis* role, rat model, 821
*Peromyscus maniculatus*, hantavirus reservoir, 1271
Phagocytosis
*H. influenzae*, nontypeable, 425
in hypertonic environments, 839
9-(2-phosphonylmethoxyethyl)adenine, for SIV infection, in macaque, 260
Piroplasmosis, in Western US, newly characterized, 1050
Plasmin(ogen) receptors, on group A streptococci, 143
*Plasmodium falciparum*
and *P. vivax*, malaria, nitrite and nitrite levels in, 1418
infection, nitric oxide in, 1417
malaria
chloroquine or quinine for, and clindamycin, 467
soluble vascular adhesion molecule 1, 710
*Plasmodium vivax*
circumsporozite protein polymorphs, 464
malaria, primaquine for, in blood stage, 932
*Pneumocystis carinii*
dihydropteroate synthase, inhibition by sulfonamides and dapsone, 456
pneumonia, neopterin and $\beta_2$-microglobulin, 1170
Pneumonia
*P. carinii*, neopterin and $\beta_2$-microglobulin, 1170
*R. equi*, in AIDS, immune response to, 1179
Pneumonitis, *C. trachomatis*, in infants, antibody response, 908
Polymerase chain reaction to deetect
*B. burgdorferi*, 668
*C. albicans*, 1062
*C. difficile*, arbitrarily primed, 661
CMV
DNA, in CSF, 623, 1334
envelope glycoprotein genotypes, 769
in semen, 222, 223
HCV RNA, 473, 1219
HHV-6 DNA, 1342
HIV-1, 416
JCV in CSF, 1138
*M. paratuberculosis*, in children, 449
*N. meningitidis*, during outbreak, 1384
*Onchocerca* DNA, 686
Polymerase chain reaction–single-strand DNA conformation assay, to detect HBV, 62
Polymorphonuclear leukocyte
influenza virus–activated, superoxide anion production, 1129
priming, in bacteremia, gram-negative, 1151
Polyomavirus, latency and human tumors, 1175
Polysaccharide, K54 capsular, effect on pathogenicity, 112
Praziquantel, and anticonvulsants, for neurocysticercosis, 689
Pregnancy, outcome, and *T. pallidum* infection, in West Africa, 701, 702
Primaquine, for *P. vivax* malaria, blood stage, 932
Progressive multifocal leukoencephalopathy, diagnosis by PCR, 1138
*Proteus mirabilis*, uropathogenicity, swarming role, 1155
Protozoan, intraerythrocytic, newly recognized, characterization, 1050
Pseudomembranous colitis, and antibiotic-associated diarrhea, *C. difficile*, therapy, 1291
*Pseudomonas aeruginosa*
LPS, 441
strain typing methods, primarily in cystic fibrosis, 134
vaccine, in CF patients, safety and immunogenicity, 1159
Puumala virus, isolation from *M. musculus*, association with HFRS, 204
Pyrimethamine, prophylaxis for *T. gondii* encephalitis, in AIDS, 384

Quinine or chloroquine, and clindamycin, for *P. falciparum* malaria, 467

Rapid plasma reagin test, in HIV-1 infection, false-positive, 1356
Red man syndrome, prospective evaluation, 700
Renal failure, chronic, response to hepatitis vaccine, 399
Resistance, zidovudine, in HIV-1 infection, long-term, 184
Respiratory syncytial virus, antibody concentrations and immune globulins, 1368
Restriction fragment length polymorphism analysis
to detect *M. tuberculosis* in HIV-infected patients, in outbreak, 189
to differentiate HCV genotypes, 473
Retinitis, viral, (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosone for, 642
Rhinovirus, colds, IL-1 levels in, 1007
*Rhodococcus equi*, pneumonia, in AIDS, immune response to, 1179
Ribosomal DNA, probe, for bacterial ribotype analysis, 1413
Rotavirus
antibodies in children, 504
and HIV-1 infections, in children with acute diarrhea, 897
protection, after natural rotavirus infection, 900
replication, effect of intestinal mucins, 1002

*Saccharomyces cerevisiae*, clinical and nonclinical isolates, comparative pathogenesis, 859
*Salmonella enteritidis*, outbreaks in US, 547
*Salmonella typhi*
infection, interleukins and TNF during, 1306

vaccine strain CVD 908, strain construction, safety, and immunogenicity, 927
*Salmonella typhimurium*, induces P glycoprotein expression, 760
Salpingitis, *C. trachomatis*, pathogenesis, monkey model, 680
Scrapie, transmission, intracerebral, to cattle, 814
Sepsis
gram-negative, inhibition of nitric oxide synthase, 343
*S. aureus*–induced, CL 184,005 for, 150
Septic shock, *E. coli*, MAb function, dog model, 553
Shiga-like toxin, action, 538
*Shigella* diarrhea, pathogenesis, 538
*Shigella dysenteriae*, type 1, panresistance and prevention, in Burundi, 1035
(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosone, for viral retinitis, 642
Simian immunodeficiency virus infection
of intestinal lymphoid tissue, rhesus macaque model, 1116
PMEA for, macaque model, 260
Soluble vascular adhesion molecule 1, in *P. falciparum* malaria, 710
Sporozoite, *P. vivax*, circumsporozite protein polymorphs, 464
*Staphylococcus aureus*
phagolysosomal alkalinization and intracellular killing, by amikacin, 330
sepsis, CL 184,005 for, 150
superantigen-producing, 1144
*Staphylococcus*, coagulase-negative, from neonates with persistent bacteremia and children with catheters, 1393
*Staphylococcus epidermidis*
antibody to, opsonic, 324
bacteremia, nosocomial transmission, neonatal, 526
polysaccharide/adhesin, 1042
Streptococci, group A
epidemiologic typing, 519
pharyngeal infection, passive protection by lipoteichoic acid, mouse model, 319
*Streptococcus pneumoniae*
antibody to, in vitamin A–deficient rats, 441
infection, invasive, serotypes, in children, 212
meningitis, epidemiology, 912
serotype distribution and antimicrobial resistance, in children, 479
*Streptococcus pyogenes*, interaction with human plasmin and plasminogen, 143
*Streptococcus sanguis*, endocarditis, amoxicillin for, 1397
Streptokinase, plasminogen, plasmin and group A streptococci, 143
*Strongyloides stercoralis* infection
and HTLV-I infections, immunoepidemiologic study, 692
ivermectin vs. thiabendazole for, 1076
Superantigen, as virulence factor, 1144
SYNSORB, as therapy for *C. difficile*–associated diarrhea, and pseudomembranous colitis, 1291

T lymphocyte
cytotoxic, in asymptomatic HBsAg carriers, 633
HSV-specific, from lesions, 956
Teicoplanin, for gram-positive bacteremia, in cancer, 350
Tetrahydrocannabinol, effect on *L. pneumophila* resistance, 1177
Thiabendazole, vs. ivermectin, for strongyloidiasis, 1076
*Toxoplasma gondii*
encephalitis
pyrimethamine for primary prophylaxis, in AIDS, 384
SCID mouse model, 375
infection, serum effect on IL-6 production, 1181
*Treponema pallidum* infection
hepatitis C, hepatitis B, and HIV infection, among non-IVDU STD clinic patients, 990
and pregnancy outcome, in West Africa, 701
Tropical spastic paraparesis, in HTLV-I, 941
Tuberculosis, Third World Congress Report, 1189
Tumor necrosis factor
in endotoxemia, association with IL-1 receptor antagonist, 665
and IL-6, role in adverse reaction after treatment for filariasis and onchocerciasis, 1071
soluble receptor, in meningococcal infection, 157
in typhoid fever, 1306
Tumor necrosis factor-$\alpha$
in CMV murine infection, 1088
in HIV-1 infection, 420
levels, in perinatal HIV-1 infection, 975
MAb, safety and pharmacokinetics, 214
soluble receptors
in HIV-1 infection, 420
as predictors of disease progression, 739
Typhoid fever, cytokines and inhibitors, 1306
Typing methods, *P. aeruginosa* strains, multicenter comparison, 134

Urethritis, *N. gonorrhoeae*, experimental, 532
Urinary tract infection
antibody-secreting cells in, 1023
*E. coli* serotypes, 119

V3 region, HIV-1, amino acid sequence, 227
Vaccine
amebiasis, 483
HAV, inactivated, safety and immunogenicity, 996
HBV, breakthrough infections and viral variant, in immunized children, 1374
HCV, response in chronic uremia, 399
influenza
cold-adapted, inactivated, efficacy, 68
cold-recombinant, trivalent, in children, 1121
in cystic fibrosis, 241
heterologous, effects of aging on response, 1125
influenza A, live attenuated, response in children, 200
influenza B, cold adapted, in high-risk adults, 402
mumps, failure and waning immunity, 77
*N. meningitidis*, polysaccharide, antibody response, 847
*P. aeruginosa*, in CF patients, safety and immunogenicity, 1159
recombinant vaccinia–HIV-1 envelope and envelope protein, response, 41
*S. typhi* CVD 908, strain construction, safety, and immunogenicity, 927
varicella, live attenuated, immune response, in children, 197
Vancomycin
for bacteremia, gram-positive, in cancer, 350
red man syndrome, prospective evaluation, 700
vaccine, live attenuated, immune response, in children, 197
Varicella-zoster virus
DNA, detection in air samples, 91
reactivation, after chickenpox in infancy, 650
*Vibrio cholerae*
genetic diversity and clonal relationships, 1412
infection, epidemic, role of produce in risk and prevention, 1381
lack of cross-protection among serotypes, 709
O139 Bengal, 230, 1029
Virulence
*E. coli*, in urosepsis, by serotype, 119
*S. epidermidis*, adhesin role, 1042

Visceral leishmaniasis, and HIV-1 infection, mononuclear cells in, 707
1,25 vitamin D, serum concentration, in HIV-1 infection, 889

*Wucheria bancrofti*, infection, DEC for, TNF and IL-6 role in adverse reaction, 1071

Yellow fever virus, neurovirulent vaccine virus, 512
*Yersinia enterocolitica*, virulence, desferrioxamine-promoted, mouse model, 562

Zidovudine
for HIV-1 exposure, postexposure prophylaxis, 478
for HIV-1 infection
cytotoxicity, embryonic, 1100
and didanosine, 9, 416, 722
fluconazole effect on, 1103
and IFN-$\alpha$, vs. zidovudine monotherapy, 1351
and nevirapine, alternating treatment, 1346
p24 antigen level as end point, 713
provirus load, 267
selection against, 611
resistance mutations, in HIV-1, 184, 411
Zygomycetes, deferoxamine for, 231